Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma

Lp, Koh; Lc, Lim; Ch, Thng

doi:10.1007/bf02780533

Cited by 16 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The disease is characterized as having a good survival but a short time to progression, and logical treatment options include polychemotherapy, with or without anthracyline, associated with rituximab. 42 …”

Section: Treatmentmentioning

confidence: 99%

Clinical Presentation and Management of Marginal Zone Lymphomas

Thiéblemont¹

2005

Hematology

109

View full text Add to dashboard Cite

Marginal-zone lymphoma (MZL) includes three subtypes depending on the site of lymphoma involvement: extranodal marginal zone B-cell lymphoma of mucosaassociated lymphoid tissue (MALT-lymphoma); splenic MZL; and nodal MZL. Beside a common cell-of-origin and similarities concerning a possible chronic antigenic stimulation by microbial pathogens and/or autoantigens, the clinical presentation is very different with symptoms related to lymphoma location. MALT and splenic MZL present with an indolent disease with good performance status, no B symptoms, and no adverse prognostic factors and are associated with long survival. Patients with nodal MZL present with a more aggressive disease and have a shorter failurefree survival. Clinical and biological prognostic factors identified in reported series are heterogeneous. The optimal treatment has yet to be defined for the three subtypes, and current strategies will be described in this review.Marginal zone B-cell lymphomas (MZL) represent a group of lymphomas whose cells originate from B lymphocytes normally present in a distinct anatomical location, the socalled "marginal zone" (MZ) of the secondary lymphoid follicles.1 These cells are anatomically localized in the lymphoid organs (spleen and lymph nodes) and in the nonlymphoid organs (mucosa-associated lymphoid tissue [MALT] or non-mucosal tissue such as skin, orbit and dura). Depending on the site of involvement, the International Lymphoma Study Group individualized three distinct subtypes of MZL: (1) extranodal MZL of MALT type, (2) splenic MZL (with or without villous lymphocytes), and (3) nodal MZL (with or without monocytoid B cells).2,3 Despite this classification, the relative rarity of these lymphomas and difficulties in distinguishing them from other low-grade lymphoma subtypes are obstacles to conducting epidemiological surveys and to describing clinical features and outcomes. Moreover, no prospective studies on large series have been published to date, making therapeutic decisions difficult. Data regarding clinical and biological prognostic markers are limited, and it is therefore difficult to predict those in whom the disease will be more aggressive. This review will present recent data describing the epidemiology, clinical features, staging, and therapy of these lymphomas. EpidemiologyMZL account for between 5% and 17% of all non-Hodgkin lymphomas (NHL) in adults depending on the series. MALT lymphoma is the most frequent of the MZL subtypes, representing 50% to 70% of MZL and 7% to 8% of NHL. The splenic and the nodal MZL represent 20% and 10% of MZL, respectively, and account for less than 1% of NHL. Most of the cases occur in adults, with a median age of approximately 60 years, except for splenic MZL with villous lymphocytes (SLVL), occurring in adults at a median age of around 70 years. [4][5][6][7][8]

show abstract

Section: Treatmentmentioning

confidence: 99%

Clinical Presentation and Management of Marginal Zone Lymphomas

Thiéblemont¹

2005

Hematology

109

View full text Add to dashboard Cite

show abstract

“…Due to the low incidence of N-type MZL, there is no definitive treatment; however, multidrug chemotherapy, including anthracycline, has been proposed based on rituximab [8]. Moreover, localized lesions have been reported to respond well to localized radiotherapy [9].…”

Section: Discussionmentioning

confidence: 99%

A case of nodal marginal zone B-cell lymphoma of the lower eyelid

Lee

Jung

2020

Arch Craniofac Surg

View full text Add to dashboard Cite

A marginal zone B-cell lymphoma is a type of B-cell lymphoma which is normally located at the margins of the secondary lymph node follicles. According to 2008 World Health Organization (WHO) classification, there are three main types classified according to the location of invasion: nodal lymphoma in the lymph nodes, splenic lymphoma in the spleen, and extranodal lymphoma in other locations. Recently, we have experienced a rare case of primary nodal marginal zone lymphoma that arose in the lower eyelid. Therefore, we report this case with a review of literature.

show abstract

“…The disease is characterized as having a good survival but a short time to progression, and logical treatment options include polychemotherapy, with or without anthracycline, associated with rituximab [45].…”

Section: Treatmentmentioning

confidence: 99%

Management of marginal zone lymphomas

Thiéblemont¹,

Coiffier

2006

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Marginal-zone lymphoma (MZL) includes three subtypes depending on the site of lymphoma involvement: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma); splenic MZL; and nodal MZL. Although there is a common cell of origin and similarities concerning a possible chronic antigenic stimulation by microbial pathogens and/or auto-antigens, the clinical presentation is very different with symptoms related to lymphoma location. MALT and splenic MZL present with an indolent disease with good performance status, no B symptoms, and no adverse prognostic factors and are associated with long survival. Patients with nodal MZL present with a shorter progression-free survival. Clinical and biological prognostic factors identified in reported series are heterogeneous. The optimal treatment has yet to be defined for the three subtypes, and current strategies are described in this review.

show abstract

Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma

Cited by 16 publications

References 12 publications

Clinical Presentation and Management of Marginal Zone Lymphomas

Clinical Presentation and Management of Marginal Zone Lymphomas

A case of nodal marginal zone B-cell lymphoma of the lower eyelid

Management of marginal zone lymphomas

Contact Info

Product

Resources

About